RBM5

Across TCGA pan-cancer cohorts, RBM5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RBM5 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RBM5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RBM5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and HNSC are the cancer types where RBM5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	IV	0.934	0.235	.024	9	view →
COAD	DFS	Median	III,IV	1.000	0.893	.033	6	view →
HNSC	DFS	Median	IV	0.706	0.904	.019	6	view →
LSCC	OS	Median	II,III,IV	0.884	0.624	.021	4	view →
CCRCC	DFS	Median	III,IV	0.712	0.471	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RBM5–PDAC (DFS)

Open the PDAC breakdown →